Mycofenolsýra Accord (Mycophenolic Acid)

• Mycofenolsýra Accord is used in immunosuppressive therapy to manage conditions where immune modulation is required.
• Organ transplant rejection: helps prevent graft rejection by inhibiting lymphocyte proliferation.
• Lupus nephritis: reduces renal inflammation and proteinuria in systemic lupus erythematosus.
• Rheumatoid arthritis: alleviates joint inflammation when conventional disease‑modifying agents are insufficient.

• Mycophenolic Acid selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the key enzyme in the de novo synthesis of guanosine nucleotides. By blocking IMPDH, the drug depletes guanosine pools required for DNA synthesis, preferentially suppressing proliferation of activated T and B lymphocytes while sparing resting cells, thereby reducing immune‑mediated graft damage and autoimmune activity.

Mycofenolsýra Accord may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea
• Diarrhea
• Vomiting
• Abdominal pain
• Headache
• Upper‑respiratory tract infections

Serious or Rare Side Effects

• Leukopenia or severe neutropenia
• Anemia
• Severe or opportunistic infections
• Hepatic dysfunction
• Increased risk of malignancy
• Progressive multifocal leukoencephalopathy (rare)

• When prescribing Mycofenolsýra Accord, clinicians should observe several precautionary measures to ensure patient safety.
• Monitor blood counts: perform regular complete blood count to detect leukopenia or anemia.
• Assess liver function: check hepatic enzymes periodically for signs of toxicity.
• Evaluate renal function: adjust dose in patients with impaired kidney function.
• Avoid use in active infection: postpone initiation until infection resolved.
• Use effective contraception: advise women of child‑bearing potential to use reliable birth control.
• Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Mycofenolsýra Accord can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Live vaccines: concurrent use may cause uncontrolled infection.
• Azathioprine: combined therapy markedly increases risk of bone‑marrow suppression.
• High‑dose corticosteroids: may amplify immunosuppression and infection risk.

Moderate Interactions (Monitor Closely)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise mycophenolic acid plasma levels.
• NSAIDs: may increase risk of gastrointestinal irritation.
• ACE inhibitors or ARBs: combined use may affect renal function.